Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Matern Fetal Neonatal Med ; 24(8): 1060-4, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21250913

ABSTRACT

OBJECTIVE: The primary outcome measure of this study was the ability of rHuEPOα therapy to reduce transfusion needs, whereas secondary outcome measures were NICU-LOS and ventilation need. METHODS: All babies with BW <1250 g and GA <30 were eligible. Thirty premature neonates were enrolled in the study (10 treated, 20 controls). rHuEPOα was administered as 300 IU/kg/dose 3 times/week subcutaneously. Iron, folic acid and Vitamin E supplementation were administered in both groups. Hematologic variables and blood sampling were recorded during the study. RESULTS: In rHuEPO group, only four (40%) premature infants required a transfusion, averaging 0.4 ±â€Š0.52 transfusions/pts. A total of 23 transfusions were administered to controls; 11 (55%) infants received one transfusion at least, 55% required multiple transfusions. The average number of transfusions/pts was statistically different (1.15  ±â€Š 1.46 vs. 0.4 ±â€Š0.52; p = 0.02), as the cumulative number of transfused patients (55% vs. 40%; p<0.001). NICU stay was not statistically different, whereas ventilation-free days were increased in EPO group (p<0.05). CONCLUSIONS: R-Hu-EPO treatment in first post-natal weeks markedly enhanced erythropoiesis in severely premature infants compared with matched controls, with a significant impact on transfusion needs. EPO group experienced also a reduction of ventilation time and, possibly, a decreased occurrence of clinical BPD.


Subject(s)
Anemia/drug therapy , Blood Transfusion/statistics & numerical data , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Infant, Premature, Diseases/drug therapy , Respiration, Artificial/statistics & numerical data , Anemia/blood , Anemia/therapy , Case-Control Studies , Combined Modality Therapy , Drug Administration Schedule , Erythropoietin/administration & dosage , Folic Acid/administration & dosage , Folic Acid/therapeutic use , Hematinics/administration & dosage , Humans , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/blood , Infant, Premature, Diseases/therapy , Infant, Very Low Birth Weight , Intensive Care Units, Neonatal , Iron/administration & dosage , Iron/therapeutic use , Length of Stay/statistics & numerical data , Treatment Outcome
2.
Int J Sports Med ; 17(3): 239-40, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8739581

ABSTRACT

In Ancient Greece determination of sex was made by direct observation of the all-male athletes participating in the Olympic Games. In 1966 the International Olympic Committee (I.O.C.) established that female athletes must submit to a complete physical examination before each international competition. In 1968 they further established that each female participant be granted a "Sex Passport" based upon the findings of a medical and gynaecological examination as well as chromosomal sex determination. The authors, whose department has been responsible for granting Sex Passports for more than 20 years, examined 364 female athletes aged 16 to 29 years using I.O.C. criteria. They found three chromatic-negative cases (0.8%). The present work indicates several scientific shortcomings of the current I.O.C. examination criteria, illustrates three chromatin-negative cases, their consequences and proposed a return to original criteria for examination except in doubtful cases.


Subject(s)
Sex Determination Analysis , Sports , Women , Adolescent , Adult , Androgen-Insensitivity Syndrome/genetics , Female , Fragile X Syndrome/genetics , Genitalia, Female/anatomy & histology , Gonadal Dysgenesis, 46,XY/genetics , Humans , Male , Physical Examination , Sex Chromatin/genetics , Sex Chromatin/isolation & purification , Sex Chromosomes/genetics , X Chromosome/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...